Trial Profile
Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-Alum) on the Progression of Type 1 Diabetes in New Onset Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs GAD65 vaccine (Diamyd) (Primary) ; Aluminium hydroxide
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms TN08; TrialNet TN08
- 05 Aug 2020 Results (n=521) of an analysis from three clinical studies: NCT00435981, NCT00529399 and NCT00723411 assessing efficacy of GAD-specific immunotherapy in presence of the GAD and insulin antibody-associated HLA haplotypes DR3-DQ2 and DR4-DQ8 published in the Diabetologia
- 04 Apr 2020 Results (N=46), exploring cellular and molecular mechanism of GAD-alum, action published in the Diabetologia
- 29 Jun 2011 Follow up is continuing for a further 12 months.